In a 24-week, multicenter, open-label trial, 506 adults recently hospitalized for heart failure were randomly assigned to mobile health management or usual care.
2
Mobile health management combined daily transmission of biometric data and symptom questionnaires with health care team review, alerts, and video consultations.
3
The primary endpoint of cardiovascular mortality or worsening heart failure occurred in 17% of the mobile health group and 41% of the usual care group.
4
Worsening heart failure occurred in 14% of patients receiving mobile health management and 39% receiving usual care; cardiovascular mortality occurred in 4% and 8%, respectively.
5
The authors noted limitations including the open-label design, lack of systematic adverse-event data, and uncertainty about staffing and workflow requirements for broader implementation.
